Lipocine (LPCN) Common Equity (2011 - 2025)
Lipocine's (LPCN) quarterly Common Equity came in at $14.5 million in Q4 2025, down 31.05% YoY from $21.0 million in Q4 2024, and up 2.37% on a QoQ basis from $14.1 million in Q3 2025.
Lipocine (LPCN) Common Equity (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Common Equity data on file, last reported at $14.5 million in Q4 2025.
- Quarterly Common Equity fell 31.05% year-over-year to $14.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.5 million (down 31.05% YoY) and the FY2025 annual result came in at $14.5 million, down 31.05% from the prior year.
- Common Equity improved to $14.5 million in Q4 2025, from $14.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $45.6 million in Q4 2021 to a low of $14.1 million in Q3 2025.
- A 5-year average of $28.3 million and a median of $26.3 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity jumped 546.92% — and 2023, when it plunged 42.84%.
- Tracing LPCN's Common Equity over 5 years: stood at $45.6 million in 2021, then retreated by 21.8% to $35.6 million in 2022, then slumped by 42.84% to $20.4 million in 2023, then grew by 3.08% to $21.0 million in 2024, then slumped by 31.05% to $14.5 million in 2025.
- The last three Common Equity figures came in at $14.5 million (Q4 2025), $14.1 million (Q3 2025), and $17.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 9.79 Bn |
| 10 | Lipocine | 11.21 Mn | -12.70 Mn | - | 14.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.48 Mn |
| Sep 30, 2025 | 14.14 Mn |
| Jun 30, 2025 | 17.13 Mn |
| Mar 31, 2025 | 19.20 Mn |
| Dec 31, 2024 | 21.00 Mn |
| Sep 30, 2024 | 19.12 Mn |
| Jun 30, 2024 | 21.21 Mn |
| Mar 31, 2024 | 23.96 Mn |
| Dec 31, 2023 | 20.37 Mn |
| Sep 30, 2023 | 22.48 Mn |
| Jun 30, 2023 | 28.55 Mn |
| Mar 31, 2023 | 31.96 Mn |
| Dec 31, 2022 | 35.63 Mn |
| Sep 30, 2022 | 37.65 Mn |
| Jun 30, 2022 | 39.89 Mn |
| Mar 31, 2022 | 42.41 Mn |
| Dec 31, 2021 | 45.57 Mn |
| Sep 30, 2021 | 32.81 Mn |
| Jun 30, 2021 | 35.75 Mn |
| Mar 31, 2021 | 42.39 Mn |